Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

Virtualware (EPA: MLVIR), a leading expert in 3D-driven enterprise software, reported a 90% increase in EBITDA to 806,000 euros, according to its unaudited results submitted ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 ...

In an editorial, J. Mocco, MD, of Mount Sinai Health System in New York City, characterized the DISTAL and ESCAPE-MeVO ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Twenty-five years ago, the bestseller “The Tipping Point” turned Malcolm Gladwell into a household name. Describing “the critical mass, the threshold, the boiling point,” Gladwell illustrates ...